Latest articles

Speakers: Peter Lakatos (Hungary), Sheila Crowe (USA) Bone mineral disease (BMD) is common in the general population, and there is an increased risk of developing disorders of BMD – osteopenia and osteoporosis – among people with gastrointestinal (GI) disorders, especially in those with inflammatory bowel disease (IBD), untreated celiac disease, end-stage cholestatic liver disease and after gastric surgery. Dr Peter Lakatos told the audience of gastroenterologists that osteopenia and osteoporosis are present in up to one-third of patients with GI diseases (15-35%), and that these patients are at an increased risk of bone fracture, at 1.4 to 3 times that of the general population. Dr Lakatos emphasised that it is…

Speakers: Sigrid Elsenbruch (Germany), Qasim Aziz (UK) The power of the placebo effect was first reported by Henry Beecher in 1955 in his seminal paper on the substitution of saline placebo for opiates in pain management when supplies of opiates were exhausted. Since then, the last 50 years have witnessed an explosion in the number of publications investigating the effects of both placebo and nocebo. The placebo effect arises from the patient’s expectations of treatment rather than the treatment itself. Dr Elsenbruch outlined the 3 main uses of placebo: as a tool for separating specific and non-specific treatment effects, to analyse the efferent and afferent pathways involved in psychological responses…

Speakers: Nicholas Talley (Australia), Annamaria Staiano (Italy), Marc Benninga (The Netherlands), Lukas van Oudenhove (Belgium)   “The definition of functional gastrointestinal disorders (FGIDs) as laid out in the Rome III criteria is now highly questionable.” This was the view expressed by Professor Nicholas Talley of the University of Newcastle, Australia when introducing his presentation on the Epidemiology of FGIDs and their overlap. He suggested that the term FGIDs is a misnomer, as the disorders are not “functional” and proposed that the disorders would be better described as syndromes of an “irritable gut”. He provided evidence that there is considerable overlap between FGIDs and transition from one disorder to another over…

Speakers: Franck Carbonnel (France), Johan Burisch (Denmark), Fergus Shanahan (Ireland) The role of gut microbiota in the pathogenesis of inflammatory bowel disease (IBD) is increasingly recognised, as evidenced by the escalating number of publications on microbiota, rising from less than 200 in 1990 to over 1200 in 2012 thus far. This fact was highlighted by Dr Fergus Shanahan when introducing his presentation on microbiota at UEG Week 2012. He noted that a healthy gut is one in which there is high microbial diversity resulting in improved performance and stability. Conversely, in the disease state the opposite is true. Moreover, the heterogeneity of IBD is reflected in the microbiota. Environmental modifiers…

Twitter

Twitter


Follow @GMFHx
Upcoming events
See all events
News archive
Access from here to the chronological archive of news of this site
Access archive
Research & Practice
Latest articles

Speakers: Peter Lakatos (Hungary), Sheila Crowe (USA) Bone mineral disease (BMD) is common in the general population, and there is an increased risk of developing disorders of BMD – osteopenia and osteoporosis – among people with gastrointestinal (GI) disorders, especially in those with inflammatory bowel disease (IBD), untreated celiac disease, end-stage cholestatic liver disease and after gastric surgery. Dr Peter Lakatos told the audience of gastroenterologists that osteopenia and osteoporosis are present in up to one-third of patients with GI diseases (15-35%), and that these patients are at an increased risk of bone fracture, at 1.4 to 3 times that of the general population. Dr Lakatos emphasised that it is…

Speakers: Sigrid Elsenbruch (Germany), Qasim Aziz (UK) The power of the placebo effect was first reported by Henry Beecher in 1955 in his seminal paper on the substitution of saline placebo for opiates in pain management when supplies of opiates were exhausted. Since then, the last 50 years have witnessed an explosion in the number of publications investigating the effects of both placebo and nocebo. The placebo effect arises from the patient’s expectations of treatment rather than the treatment itself. Dr Elsenbruch outlined the 3 main uses of placebo: as a tool for separating specific and non-specific treatment effects, to analyse the efferent and afferent pathways involved in psychological responses…

Speakers: Nicholas Talley (Australia), Annamaria Staiano (Italy), Marc Benninga (The Netherlands), Lukas van Oudenhove (Belgium)   “The definition of functional gastrointestinal disorders (FGIDs) as laid out in the Rome III criteria is now highly questionable.” This was the view expressed by Professor Nicholas Talley of the University of Newcastle, Australia when introducing his presentation on the Epidemiology of FGIDs and their overlap. He suggested that the term FGIDs is a misnomer, as the disorders are not “functional” and proposed that the disorders would be better described as syndromes of an “irritable gut”. He provided evidence that there is considerable overlap between FGIDs and transition from one disorder to another over…

Speakers: Franck Carbonnel (France), Johan Burisch (Denmark), Fergus Shanahan (Ireland) The role of gut microbiota in the pathogenesis of inflammatory bowel disease (IBD) is increasingly recognised, as evidenced by the escalating number of publications on microbiota, rising from less than 200 in 1990 to over 1200 in 2012 thus far. This fact was highlighted by Dr Fergus Shanahan when introducing his presentation on microbiota at UEG Week 2012. He noted that a healthy gut is one in which there is high microbial diversity resulting in improved performance and stability. Conversely, in the disease state the opposite is true. Moreover, the heterogeneity of IBD is reflected in the microbiota. Environmental modifiers…

Meet our board of experts